Common CYP2D6 polymorphisms affecting alternative splicing and transcription: Long-range haplotypes with two regulatory variants modulate CYP2D6 activity

Human Molecular Genetics

Volumn 23, Issue 1, 2014, Pages 268-278

  Wang, Danxin ^a   Poi, Ming J ^b   Sun, Xiaochun ^a   Gaedigk, Andrea ^c   Leeder, J Steven ^c   Sadee, Wolfgang ^a  

^a School of Medicine   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; GENOMIC DNA; MESSENGER RNA;

ALTERNATIVE RNA SPLICING; ARTICLE; CONTROLLED STUDY; ENHANCER REGION; ENZYME ACTIVITY; EXON; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INTRON; NULL ALLELE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICING DEFECT;

ALTERNATIVE SPLICING; CYTOCHROME P-450 CYP2D6; EXONS; GENETIC LOCI; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HEP G2 CELLS; HUMANS; LINKAGE DISEQUILIBRIUM; LIVER; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC;

EID: 84890340211     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt417     Document Type: Article

References (43)

1. Phillips, K.A., Veenstra, D.L., Oren, E., Lee, J.K. and Sadee, W. (2001) Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA, 286, 2270-2279.
2. Griese, E.U., Zanger, U.M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuven, T. and Eichelbaum, M. (1998) Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics, 8, 15-26.
3. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J. and Leeder, J.S. (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin.Pharmacol. Ther., 83, 234-242.
4. Crews, K.R., Gaedigk, A., Dunnenberger, H.M., Klein, T.E., Shen, D.D., Callaghan, J.T., Kharasch, E.D. and Skaar, T.C. (2012) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther., 91, 321-326.
5. Hicks, J.K., Swen, J.J., Thorn, C.F., Sangkuhl, K., Kharasch, E.D., Ellingrod, V.L., Skaar, T.C., Muller, D.J., Gaedigk, A. and Stingl, J.C. (2013) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther., 93, 402-408
6. Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J.S., Johnson, J.A., Roden, D.M., Klein, T.E. and Shuldiner, A.R. (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther., 90, 328-332.
7. Bock, K.W., Schrenk, D., Forster, A., Griese, E.U., Morike, K., Brockmeier, D. and Eichelbaum, M. (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics, 4, 209-218.
8. Raimundo, S., Toscano, C., Klein, K., Fischer, J., Griese, E.U., Eichelbaum, M., Schwab, M. and Zanger, U.M. (2004) A novel intronic mutation, 2988G.A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther., 76, 128-138.
9. Yu, A., Kneller, B.M., Rettie, A.E. and Haining, R.L. (2002) Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms. J. Pharmacol. Exp. Ther., 303, 1291-1300.
10. Marcucci, K.A., Pearce, R.E., Crespi, C., Steimel, D.T., Leeder, J.S. and Gaedigk, A. (2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1),CYP2D6.2,andCYP2D6.17activities toward modelCYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine. Drug Metab. Dispos., 30, 595-601.
11. Sakuyama, K., Sasaki, T., Ujiie, S., Obata, K., Mizugaki, M., Ishikawa, M. and Hiratsuka, M. (2008) Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57). Drug Metab. Dispos., 36, 2460-2467.
12. Toscano, C., Klein, K., Blievernicht, J., Schaeffeler, E., Saussele, T., Raimundo, S., Eichelbaum, M., Schwab, M. and Zanger, U.M. (2006) Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronicSNP2988G.A: evidence for modulation of splicing events. Pharmacogenet. Genomics, 16, 755-766.
13. Denson, J., Wu, Y., Yang, W.and Zhang, J. (2005) Inter-individual variation of several cytochrome P450 2D6 splice variants in human liver. Biochem. Biophys. Res. Commun., 330, 498-504.
14. Raimundo, S., Fischer, J., Eichelbaum, M., Griese, E.U., Schwab, M. and Zanger, U.M. (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics, 10, 577-581.
15. Zanger, U.M., Fischer, J., Raimundo, S., Stuven, T., Evert, B.O., Schwab,M. and Eichelbaum, M. (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 11, 573-585.
16. Gaedigk, A., Bhathena, A., Ndjountche, L., Pearce, R.E., Abdel-Rahman, S.M., Alander, S.W., Bradford, L.D., Rogan, P.K. and Leeder, J.S. (2005) Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J., 5, 173-182.
17. Schadt, E.E., Molony, C., Chudin, E., Hao, K., Yang, X., Lum, P.Y., Kasarskis, A., Zhang, B., Wang, S., Suver, C. et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol., 6, e107.
18. Yang, X., Zhang, B., Molony, C., Chudin, E., Hao, K., Zhu, J., Gaedigk, A., Suver, C., Zhong, H., Leeder, J.S. et al. (2010) Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res., 20, 1020-1036.
19. Mendell, J.T., ap Rhys, C.M. and Dietz, H.C. (2002) Separable roles for rent1/hUpf1 in altered splicing and decay of nonsense transcripts. Science, 298, 419-422.
20. Wang, D., Guo, Y., Wrighton, S.A., Cooke, G.E. and Sadee, W. (2011) Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J., 11, 274-286.
21. Wang, D., Johnson, A.D., Papp, A.C., Kroetz, D.L. and Sadee, W. (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C.T affects mRNA stability. Pharmacogenet. Genomics, 15, 693-704.
22. Wang, D., Para, M.F., Koletar, S.L. and Sadee, W. (2011) Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. Pharmacogenet. Genomics, 21, 652-664.
23. Wang, D., Chen, H., Momary, K.M., Cavallari, L.H., Johnson, J.A. and Sadee, W. (2008) Regulatory polymorphism in vitaminKepoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood, 112, 1013-1021.
24. Dunham, I., Kundaje, A., Aldred, S.F., Collins, P.J., Davis, C.A., Doyle, F., Epstein, C.B., Frietze, S., Harrow, J., Kaul, R. et al. (2012) An integrated encyclopedia of DNA elements in the human genome. Nature, 489, 57-74.
25. Dekker, J., Rippe, K., Dekker, M. and Kleckner, N. (2002) Capturing chromosome conformation. Science, 295, 1306-1311.
26. Abduljalil, K., Frank, D., Gaedigk, A., Klaassen, T., Tomalik-Scharte, D., Jetter, A., Jaehde, U., Kirchheiner, J. and Fuhr, U. (2010) Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin. Pharmacol. Ther., 88, 643-651.
27. Liu, H.X., Cartegni, L., Zhang, M.Q. and Krainer, A.R. (2001)Amechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat. Genet., 27, 55-58.
28. Sanyal, A., Lajoie, B.R., Jain, G. and Dekker, J. (2012) The long-range interaction landscape of gene promoters. Nature, 489, 109-113.
29. Oscarson, M., Hidestrand, M., Johansson, I. and Ingelman-Sundberg, M. (1997) A combination of mutations in the CYP2D6 * 17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol., 52, 1034-1040.
30. Sadee, W. (2012) The relevance of "missing heritability" in pharmacogenomics. Clin. Pharmacol. Ther., 92, 428-430.
31. Papp, A.C., Pinsonneault, J.K., Wang, D., Newman, L.C., Gong, Y., Johnson, J.A., Pepine, C.J., Kumari, M., Hingorani, A.D., Talmud, P.J. et al. (2012) Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS ONE, 7, e31930.
32. Smith, R.M., Alachkar, H., Papp, A.C., Wang, D., Mash, D.C., Wang, J.C., Bierut, L.J. and Sadee, W. (2011) Nicotinic alpha5 receptor subunit mRNA expression is associated with distant 5 ' upstream polymorphisms. Eur. J. Hum. Genet., 19, 76-83.
33. Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L.L. and Ingelman-Sundberg, M. (2001) Characterization of the CYP2D6 * 29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. Pharmacogenetics, 11, 417-427.
34. Wennerholm, A., Dandara, C., Sayi, J., Svensson, J.O., Abdi, Y.A., Ingelman-Sundberg, M., Bertilsson, L., Hasler, J. and Gustafsson, L.L. (2002) The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin. Pharmacol. Ther., 71, 77-88.
35. Shen, H., He, M.M., Liu, H., Wrighton, S.A., Wang, L., Guo, B. and Li, C. (2007) Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 35, 1292- 1300.
36. Sistonen, J., Fuselli, S., Levo, A. and Sajantila, A. (2005) CYP2D6 genotyping by a multiplex primer extension reaction. Clin. Chem., 51, 1291-1295.
37. Gaedigk, A., Ndjountche, L., Divakaran, K., Dianne Bradford, L., Zineh, I., Oberlander, T.F., Brousseau, D.C., McCarver, D.G., Johnson, J.A., Alander, S.W. et al. (2007) Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin.Pharmacol. Ther., 81, 242-251.
38. Gaedigk, A., Jaime, L.K., Bertino, J.S. Jr, Berard, A., Pratt, V.M., Bradfordand, L.D. and Leeder, J.S. (2010) Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants. Front. Pharmacol., 1, 121.
39. Gaedigk, A., Fuhr, U., Johnson, C., Berard, L.A., Bradford, D. and Leeder, J.S. (2010) CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics, 11, 43-53.
40. Gaedigk, A., Twist, G.P. and Leeder, J.S. (2012) CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR. Pharmacogenomics, 13, 91-111.
41. Wang, D., Papp, A.C., Binkley, P.F., Johnson, J.A. and Sadee, W. (2006) Highly variablemRNAexpression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet. Genomics, 16, 735-745.
42. Ramamoorthy, A., Flockhart, D.A., Hosono, N., Kubo, M., Nakamura, Y. and Skaar, T.C. (2010) Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenet. Genomics, 20, 451-454.
43. Hagege, H., Klous, P., Braem, C., Splinter, E., Dekker, J., Cathala, G., de Laat, W. and Forne, T. (2007) Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat. Protoc., 2, 1722-1733.